.jpg)
1 hour ago
2
Article content
HALIFAX, Nova Scotia, Sept. 11, 2026 (GLOBE NEWSWIRE) — Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF), an oncology company developing a therapy to increase the limited efficacy of immunotherapy drugs, today announced that David Regan, CEO, will present live at the OTC Markets’ Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 17th, 2026.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
DATE: September 17th
Article content
Article content
TIME: 11:00 am EDT
Article content
Article content
Schedule 1×1 meetings here.
Article content
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
Article content
Article content
Mr. Regan will be presenting on Sona’s promising clinical stage, solid cancer treatment, Targeted Hyperthermia Therapy, and how it may enable greater efficacy of some of today’s blockbuster drugs and thereby return significant value to investors.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Article content
Article content
Recent Company Highlights
Article content
- Sona’s Targeted Hyperthermia Therapy (“THT”) caused an immune system response in 8/10 biopsied tumors, with 6/10 no longer showing signs of cancer, in late stage melanoma patients who had failed on standard immunotherapy drugs.
- Gearing up for a study to assess the further benefits and safety of THT when combined with immunotherapy drugs in patients that previously failed on them.
- THT, which used inert gold nanorods to prime tumors, has shown excellent safety.
- Clinical strategy is supported by significant pre-clinical research published in peer-reviewed scientific journals and an experienced board and management team.
Article content
Article content
About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona’s gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion, an approach aligned with the melanoma research community’s active focus on converting immunogenically ‘cold’ tumors, which resist immunotherapy, into ‘hot’ tumors that the immune system can recognize and attack, thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Article content
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (“CTAB”) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.
English (US)